Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Food First Approach to Stimulate Muscle Protein Synthesis in Healthy Adults (Salmon)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03870165
Recruitment Status : Completed
First Posted : March 11, 2019
Last Update Posted : September 28, 2020
Sponsor:
Information provided by (Responsible Party):
Nicholas Burd, University of Illinois at Urbana-Champaign

Brief Summary:
In a crossover design 10 young healthy adults (20-35 y) will receive stable isotope tracer infusions and perform a single bout of resistance exercise. Immediately after exercise participants will ingest either 3.5 oz of Salmon fillet or its constituent macronutrients as isolated amino acids and fat. Repeated blood and breath samples as well as muscle biopsies will be collected to determine whole body amino acid kinetics, muscle amino acid transporters, anabolic signalling and myofibrillar protein synthesis rates during the trials

Condition or disease Intervention/treatment Phase
Hypertrophy Behavioral: Resistance exercise Other: Salmon Dietary Supplement: Isolated amino acids and fatty acids Not Applicable

Detailed Description:

On both infusion trials, participants will report to the laboratory at 0700 h after an overnight fast. Upon arrival to the lab, the participant will fill out a questionnaire and a baseline breath sample will be collected to determine 13CO2 enrichment by isotope ratio mass spectrometry. A Teflon catheter will be inserted into the antecubital vein for a baseline blood sample (t=-210) and then participants will receive priming doses of NaH13CO2 (2.35 µmol·kg-1), L-[1-13C]leucine (7.6 µmol·kg-1), and L-[ring-2H5]phenylalanine (2.0 µmol·kg-1). Subsequently, a continuous intravenous solution of L-[1-13C]leucine (0.10 µmol·kg-1·min-1) and L-[ring-2H5]phenylalanine (0.05 µmol·kg-1·min-1) will be initiated (t=-210) and maintained over the infusion trials. A second Teflon catheter will be inserted into a heated dorsal vein for repeated arterialized blood sampling and remained patent by a 0.9% saline drip. Breath samples and arterialized blood samples will be collected every 30 to 60 minutes during the postabsorptive and postprandial states. In the post-absorptive state of infusion trial 1, muscle biopsies will be collected at t=-150 and -30 min of infusion to determine basal-state myofibrillar protein synthesis rates, relative skeletal muscle amino acid transporter content, and anabolic-related signaling. In the subsequent cross-over trial only 1 muscle biopsy will be collected at t=-30 for Western blot analysis and postabsorptive myofibrillar protein-bound tracer enrichment. After collection of the resting muscle biopsy at t=-30 for both trials, the participants will perform resistance exercise that consists of 4 sets of 10-12 repetitions or to muscular failure at 65-70% of 1-RM for both leg press and leg extension exercise.

Immediately after the completion of the exercise bout, participants will ingest either 3.5 oz of Salmon fillet or a matched isolated amino acid and fat mixture (t=0). Completion of the meal will mark the start of the postprandial stage and additional muscle biopsies will be collected at t=120 and t=300.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Food First Approach to Stimulate Muscle Protein Synthesis in Healthy Adults
Actual Study Start Date : March 1, 2019
Actual Primary Completion Date : November 22, 2019
Actual Study Completion Date : November 22, 2019

Arm Intervention/treatment
Active Comparator: Salmon
After resistance exercise, participants will ingest 3.5 oz of salmon fillet (21g protein, 24g fat) cooked sous-vide.
Behavioral: Resistance exercise
Participants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture

Other: Salmon
Participants will ingest salmon immediately after resistance exercise

Experimental: Isolated mixture
After resistance exercise, participants will ingest an isolated amino acid and fatty acid mixture matched to the amino acid and fatty acid content of 3.5 oz salmon fillet.
Behavioral: Resistance exercise
Participants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture

Dietary Supplement: Isolated amino acids and fatty acids
Participants will ingest a mixture of isolated amino acids and fatty acids immediately after resistance exercise




Primary Outcome Measures :
  1. Fractional synthetic rate of myofibrillar proteins [ Time Frame: Postabsorptive for 3 hours, postprandial for 5 hours. ]
    Myofibrillar protein synthesis rates will be assessed during the postabsorptive period for 3 hr and during the 5 hr after the ingestion of the experimental interventions. This will allow us to assess the change from the postabsorptive to the postprandial period.


Secondary Outcome Measures :
  1. Phosphorylation of muscle anabolic signaling [ Time Frame: Baseline and at 2 and 5 hours after protein ingestion ]
    Phosphorylation of anabolic signaling pathways will be assessed in the fasted state and at 2 and 5 hr after the ingestion of the experimental interventions.

  2. Exogenous rate of leucine appearance [ Time Frame: 5 hour postprandial phase ]
    Leucine oxidation rates will be assessed in the fasted state and at multiple time points in the postprandial phase.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 20-35 years
  • Recreationally-active adults: ≥ 30 min of physical activity at moderate intensity ≥ 3 times per week
  • English fluency

Exclusion Criteria:

  • Smoking
  • Known allergies to fish consumption
  • Vegans
  • Diagnosed GI tract diseases
  • Arthritic conditions
  • A history of neuromuscular problems
  • Diagnosed cognitive impairments
  • Recent (1 year) participation in amino acid tracer studies
  • Predisposition to hypertrophic scarring or keloid formation
  • Individuals on any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications).
  • High blood pressure (Systolic > 140 mm HG; Diastolic > 90 mm HG)
  • Alcohol consumption >10 drinks per week
  • Metabolic disorders (e.g., Metabolic Syndrome, diabetes, thyroid diseases)
  • Consumption of thyroid, androgenic or other medications known to affect endocrine function
  • Consumption of ergogenic-leves of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation
  • Currently pregnant
  • A suboptimal diet quality score as assessed by ASA24 dietary records
  • Asthma
  • Hypogonadism
  • Cardiovascular disease, arrhythmias

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03870165


Locations
Layout table for location information
United States, Illinois
Freer Hall
Urbana, Illinois, United States, 61801
Sponsors and Collaborators
University of Illinois at Urbana-Champaign
Investigators
Layout table for investigator information
Principal Investigator: Nicholas A Burd, PhD University of Illinois at Urbana-Champaign
Layout table for additonal information
Responsible Party: Nicholas Burd, Assistant Professor, University of Illinois at Urbana-Champaign
ClinicalTrials.gov Identifier: NCT03870165    
Other Study ID Numbers: 19293
First Posted: March 11, 2019    Key Record Dates
Last Update Posted: September 28, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertrophy
Pathological Conditions, Anatomical